1 MARCH 2026

INCATE Stage I Award

Veirulence is an INCATE (INCubator for Antibacterial Therapies in Europe) stage I winner. INCATE provide support by providing advice, community and funding to accelerate AMR innovation, with a focus on new treatments. The €10,000 award will contribute to the cost of our proof-of-concept study.

LinkedIn announcement → More information →
10 FEBRUARY 2026

CatapultRx Grant Funding

We are pleased to be awarded the grant by CPI as part of the CatapultRx: Medicines Manufacturing Start and Scale programme, which will be delivered in partnership with the Medicines Discovery Catapult. The award will explore the platform-like potential of PDE targets through new methodology development.

3 NOVEMBER 2025

Vinnova grant — DOUBLE BARRIER

We are pleased to be awarded a grant by Vinnova as part of an international collaboration with Sahlgrenska University Hospital, Imperial College London, the National Institutes of Health, and Research Institutes of Sweden. The DOUBLE BARRIER project integrates AI-driven multi-omics diagnostics and next-generation prevention strategies to combat bacterial infections and AMR.

LinkedIn announcement → More information →